Health knowledge made personal
Join this community!
› Share page:
Go
Search posts:

DPEP1 and TPX2 as Prognostic Biomarkers for Pancreatic Ductal Adenocarcinoma

Posted Nov 17 2011 7:00pm

Description of Invention:
Scientists at NIH have developed prognostic biomarkers and a candidate therapeutic target for pancreatic ductal adenocarcinoma (PDAC). PDAC is a devastating cancer, and patients have an average survival of six months. The 5-year survival for PDAC patients is only 6%. This high lethality in pancreatic cancer is due to the late diagnosis and lack of any effective treatment. Greater than 80% of patients are diagnosed in an advanced stage of the disease. The instant invention is a discovery of biomarkers to make prognostic conclusions about the progression of PDAC by measuring the expression of DPEP1 and TPX2. Patients with decreased DPEP1 and increased TPX2 expression have poorer outcome. Furthermore, DPEP1 and TPX2 are controlled by the MAPK pathway. A MAPK inhibitor can be used as a treatment because it can lead to increased DPEP1 and decreased TPX2 expression, which is associated with better survival.

Applications:
  • Prognostic biomarker to identify high-risk patients
  • Identification of MAPK inhibitor(s) altering DPEP1 and TPX2 expression


Advantages:
  • Combination of measuring DPEP1 and TPX2 expression levels results in improved prognosis prediction
  • Development of expression level patterns during tumorigenesis that are representative of PDAC


Development Status:
In vivo data available (human)

Inventors:
Syed Perwez Hussain (NCI)
Geng Zhang (NCI)


Patent Status:
HHS, Reference No. E-171-2011/0
US, Application No. 61/512,302 filed 27 Jul 2011


Relevant Publication:
  1. DPEP1 and TPX2 as Independent Predictors of Cancer-Specific Mortality in Pancreatic Ductal Adenocarcinoma, submitted April 2011.



For Licensing Information Please Contact:
Uri Reichman Ph.D., M.B.A.
NIH Office of Technology Transfer
6011 Executive Blvd. Suite 325 Room 26,
Rockville, MD 20852
United States
Email: reichmau@mail.nih.gov
Phone: 301-435-4616
Fax: 301-402-0220


Ref No: 2338

Updated: 11/2011

Post a comment
Write a comment:

Related Searches